Table 3.
Comparison of HIV/HCV coinfected patients who underwent transient elastography in whom HCV treatment was initiated vs. patients who did not undergo HCV treatment
| Patient characteristics | All patients (n = 114) |
No treatment (n = 72) |
Treatment (n = 42) |
P-value |
|---|---|---|---|---|
| Epidemiological characteristics | ||||
| Sex | ||||
| Male | 68% (77/114) | 75% (54/72) | 55% (23/42) | 0.026 |
| Female | 33% (37/114) | 25% (18/72) | 45% (19/42) | |
| Age | 43.5 (17.7) | 41.0 (16.3) | 46.75 (16.9) | 0.078 |
| Transmission | ||||
| MSM | 7% (8/114) | 6% (4/72) | 10% (4/42) | 0.468 |
| IVDU | 71% (81/114) | 74% (53/72) | 67% (28/42) | |
| Heterosexual | 17% (19/114) | 14% (10/72) | 21% (9/42) | |
| Others | 5% (6/114) | 7% (5/72) | 2% (1/42) | |
| Laboratory parameters | ||||
| Hemoglobin (g dl−1) | 13.8 (2.85) | 13.9 (2.18) | 13.6 (3.17) | 0.106 |
| Platelet count (G l−1) | 200 ± 74.6 | 206 ± 66 | 189 ± 87.2 | 0.232 |
| White blood cell count (G l−1) | 6.54 ± 2.67 | 6.76 ± 2.67 | 6.15 ± 2.66 | 0.238 |
| Prothrombin time (%) | 93 (33.5) | 89 (32.0) | 98 (43.5) | 0.589 |
| Albumin (g dl−1) | 42.91 ± 4.66 | 43.35 ± 4.99 | 42.14 ± 3.95 | 0.184 |
| Creatinine (mg dl−1) | 0.84 (0.24) | 0.81 (0.18) | 0.90 (0.35) | 0.102 |
| Bilirubin (mg dl−1) | 0.50 (0.46) | 0.50 (0.33) | 0.52 (0.58) | 0.920 |
| AST (U l−1) | 43.5 (27.3) | 47.0 (33.0) | 39.5 (25.3) | 0.203 |
| ALT (U l−1) | 41.0 (28.5) | 45.0 (36.8) | 37.5 (24.8) | 0.102 |
| GGT (U l−1) | 76.0 (86.0) | 77.5 (86.3) | 72.0 (83.0) | 0.960 |
| HIV infection parameters | ||||
| CD4+ T‑lymphocyte count (cells μl −1 ) | 522.53 ± 272.21 | 514.76 ± 256.03 | 535.98 ± 301.02 | 0.693 |
| HIV-RNA <50 copies ml −1 | 74% (84/113) | 72% (51/71) | 79% (33/42) | 0.428 |
| HIV-RNA <400 copies ml −1 | 89% (100/113) | 86% (61/71) | 93% (39/42) | 0.264 |
| cART | 95% (108/114) | 92% (66/72) | 100% (42/42) | 0.084 |
| PI | 44% (48/108) | 53% (35/66) | 31% (13/42) | 0.024 |
| N(t)RTI | 94% (102/108) | 96% (63/66) | 93% (39/42) | 0.676 |
| NNRTI | 21% (23/108) | 23% (15/66) | 19% (8/42) | 0.649 |
| II/EI | 35% (38/108) | 23% (15/66) | 55% (23/42) | 0.001 |
| HCV infection parameters | ||||
| HCV-RNA (log IU ml −1 ) | 6.0 (1.07) | 5.97 (1.05) | 6.11 (1.12) | 0.645 |
| HCV genotype | 94% (107/114) | 90% (65/72) | 100% (42/42) | – |
| 1 | 56% (60/107) | 57% (37/65) | 55% (23/42) | 0.687 |
| 2 | 0% (0/107) | 0% (0/65) | 0% (0/42) | |
| 3 | 32% (34/107) | 29% (19/65) | 36% (15/42) | |
| 4 | 12% (13/107) | 14% (9/65) | 9% (4/42) | |
| FIB-4 | ||||
| <1.45 | 50% (57/114) | 54% (39/72) | 43% (18/42) | 0.244 |
| ≥1.45 | 50% (57/114) | 46% (33/72) | 57% (24/42) | 0.244 |
| Liver stiffness | ||||
| F0/F1 (<7.1 kPa) | 42% (48/114) | 60% (43/72) | 12% (5/42) | 0.001 |
| F2 (≥7.1 and <9.5 kPa) | 31% (35/114) | 24% (17/72) | 43% (18/42) | 0.032 |
| F3 (≥9.5 and <12.5 kPa) | 7% (8/114) | 3% (2/72) | 14% (6/42) | 0.028 |
| F4 (≥12.5 kPa) | 20% (23/114) | 14% (10/72) | 31% (13/42) | 0.029 |
| Significant liver fibrosis (≥7.1 kPa) | 58% (66/114) | 40% (29/72) | 88% (37/42) | 0.001 |
| Advanced liver fibrosis (≥9.5 kPa) | 27% (31/114) | 17% (12/72) | 45% (19/42) | 0.001 |
ALT alanine transaminase, AST aspartate transaminase, cART combined antiretroviral therapy, EI entry inhibitors, GGT gamma-glutamyl transpeptidase, GT genotype, HCV hepatitis C virus, HIV human immunodeficiency virus, II integrase inhibitors, IVDU intravenous drug abuse, MSM men who have sex with men, NNRTI non-nucleoside reverse transcriptase inhibitors, N(t)RTIs nucleos(t)idic reverse transcriptase inhibitors, PI protease inhibitor